田攀文 教授
四川大学华西医院
医学博士、主任医师、博士生导师
四川大学华西医院呼吸与危重症医学科/肺癌中心医疗组长
四川省学术与技术带头人后备人选
中国抗癌协会肺癌专业委员会青年委员
中国医师协会临床精准医疗委员会青年委员
四川省抗癌协会肿瘤呼吸病学专委会副主任委员
四川省医师协会呼吸医师分会青委会副主任委员
获国家科技进步奖二等奖，四川省科技进步奖一等奖
主持国家自然科学基金面上项目、四川省科技厅重点项目等
参考文献
[1].NCCN Guidelines. Non-Small Cell Lung Cancer v2. 2020
[2].中国临床肿瘤学会(CSCO)原发性肺癌诊疗指南2020
[3].Planchard D, et al. ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019
[4]. Wu YL, Herbst RS, Mann H,et al. ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection. Clin Lung Cancer. 2018 Jul;19(4):e533-e536
[5]. Camidge DR, et al. 2018 ASCO Abstract 9043.
[6]. Peters S, et al. N Engl J Med. 2017 Aug 31;377(9):829-838.
[7]. Takiguchi, et al. ASCO 2017.
[8]. Solomon BJ, et al. N Engl J Med. 2014 Dec 4;371(23):2167-77.
[9]. Wu YL, et al. J Thorac Oncol 2018 Oct;13(10):1539-1548.
[10]. De Castro G, et al. WCLC 2016 PL03.07.
[11]. Cho, et al. WCLC 2017 Abstract OA 05.07.
[12]. Watanabe SC, et al. Lung Cancer 2016;17:528-34.
[13]. Zhang C, et al. J Thorac Oncol. 2019 Apr;14(4):726-731.
[14]. Shaw AT, et al. N Engl J Med 2014 27; 370(13): 1189-97.
[15]. Wen-Zhao Zhong, et al. 2021 WCLC Abstract WS06.03
[16]. Wen-Zhao Zhong et al. ournal of Thoracic Oncology Vol. 15 No. 6：e95-e99
[17]. Solomon, et al. Abstract TPS8569.
[18].Dziadziuszko R, Mok T, Peters S, et al. Blood first assay screening trial (BFAST) in treatment-naive advanced or metastatic nsclc: Initial results of the phase 2 ALK-positive cohort[J]. Journal of Thoracic Oncology, 2021.
[19].Christopoulos P, Endris V, Bozorgmehr F, et al. EML4‐ALK fusion variant V3 is a high‐risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK non‐small cell lung cancer[J]. International Journal of Cancer, 2018, 142(12): 2589-2598.
[20].Yoshida T, Oya Y, Tanaka K, et al. Differential crizotinib response duration among ALK fusion variants in ALK-positive non–small-cell lung cancer[J]. Journal of Clinical Oncology, 2016, 34(28): 3383-3389.
[21].Camidge D R, Niu H, Kim H R, et al. Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L[J]. Journal of Clinical Oncology, 2020, 38(15_suppl): 9517.
[22].Cha Y J, Kim H R, Shim H S. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants[J]. Journal of Translational Medicine, 2016, 14(1): 1-10.
[23].Camidge DR, Kim HR, Ahn MJ et al. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. J Clin Oncol. 2020 Nov 1;38(31):3592-3603.
[24]. Azusa Tanimoto, Shingo Matsumoto, Shinji Takeuchi et al.Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/ TP53-Mutant NSCLC via Noxa Expression. Clin Cancer Res. 2021 Mar 1;27(5):1410-1420.
[25]. Li M, Tang Q, Chen S, et al. A novel HIP1-ALK fusion variant in lung adenocarcinoma showing resistance to Crizotinib[J]. Lung Cancer, 2021, 151: 98-100.
[26].Wei Peng, Si Li, Lijian Li, et al. A Novel LINC00478/LINC01549 Intergenic Region-
ALK Fusion Responded Well to Alectinib in a Patient With Lung Adenocarcinoma. JTO Clin Res Rep. 2020 Oct 17;2(1):100112
[27].Lirong Liu, Fangfang Hou, Yufeng Liu et al. A Case of Lung Adenocarcinoma Response to Alectinib Harboring a Rare EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK. J Natl Compr Canc Netw. 2021 Nov 11;1-5.
[28]. 2021 AACR
[29].NATURE COMMUNICATIONS | (2021) 12:1261 |
[30].National Comprehensive Cancer Network, NCCN Guidelines Non-Small Cell Lung Cancer (Version 6) 2018. 2.Socinski MA, et al. ASCO 2018 Abstract 9002.
[31].Clin Cancer Res. 2020 Feb 21.
*此文仅用于向医学人士提供科学信息，不代表本平台观点
